Multiple sclerosis: time for early treatment with high-efficacy drugs.

"Declarations Conflicts of interestKS has received personal compensation for consulting from Biogen, Celgene, GeNeuro, Merck, Novartis, Polpharma, Sanofi, Roche, TG Therapeutics, and received research support from Merck and Roche. BC has received personal compensation for consulting from Alexion, Atara, Autobahn, Avotres, Biogen, EMD Serono, Horizon, Neuron23, Novartis, Sanofi, TG Therapeutics and Therini and received research support from Genentech. MB served on scientific advisory boards for Biogen, Novartis and Genzyme and has received conference travel support from Biogen and Novartis. He serves on steering committees for trials conducted by Novartis. His institution has received research support from Biogen, Merck and Novartis. AT received personal compensation for consulting from Sandoz Global Advisory and Novartis; and has received fees (paid to institution) for serving on a steering committee for Eisai Co Ltd, HPH received fees for serving on steering and data monitoring committees from BayerHealthcare, Biogen, BMS Celgene, GeNeuro, Merck, Imcyse, Novartis, Roche, TG Therapeutics, VielaBio with approval by the Rector of Heinrich-Heine-University. Conflicts of interest KS has received personal compensation for consulting from Biogen, Celgene, GeNeuro, Merck, Novartis, Polpharma, Sanofi, Roche, TG Therapeutics, and received research support from Merck and Roche. BC has received personal compensation for consulting from Alexion, Atara, Autobahn, Avotres, Biogen, EMD Serono, Horizon, Neuron23, Novartis, Sanofi, TG Therapeutics and Therini and received research support from Genentech. MB served on scientific advisory boards for Biogen, Novartis and Genzyme and has received conference travel support from Biogen and Novartis. He serves on steering committees for trials conducted by Novartis. His institution has received research support from Biogen, Merck and Novartis. AT received personal compensation for consulting from Sandoz Global Advisory and Novartis; and has received fees (paid to institution) for serving on a steering committee for Eisai Co Ltd, HPH received fees for serving on steering and data monitoring committees from BayerHealthcare, Biogen, BMS Celgene, GeNeuro, Merck, Imcyse, Novartis, Roche, TG Therapeutics, VielaBio with approval by the Rector of Heinrich-Heine-University."